Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study - Takeaways - MDSpire

Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study

  • By

  • Jose M. Vela-Ruiz

  • Zaida Morante

  • Yomali Ferreyra

  • Marco A. Galvez-Villanueva

  • Fernando Valencia

  • J. Jhanina Campos-Tineo

  • Mariana Callapiña De Paz

  • Ariana Alessandra Córdova-Salazar

  • Pool Marcos-Carbajal

  • Joan M. Moreno Lujan

  • Andy R. Pantoja Lazaro

  • Laura G. Escobar Caipo

  • Gustavo A. Flores Trujillo

  • Teresa N. Cusma Quintana

  • Jhony A. De La Cruz-Vargas

  • Henry L. Gomez

  • Alonso Soto

  • June 9, 2026

  • 0 min

Share

  • 1

    Breast cancer is the most prevalent cancer among women in Peru, with approximately 7,797 new cases reported annually.

  • 2

    The study analyzed plasma cytokine profiles in 88 Peruvian women with clinical stage II–III breast cancer.

  • 3

    Cytokine levels, including FGF BASIC and IL-12 P40, were significantly associated with treatment response and molecular subtypes.

  • 4

    Lower levels of FGF BASIC were linked to a higher likelihood of achieving complete pathological response in breast cancer patients.

  • 5

    This research enhances understanding of cytokine profiles as potential biomarkers for treatment response in Peruvian breast cancer patients.

Original Source(s)

Plasma cytokine profiles in breast cancer patients and their association with therapeutic response in Peru: a prospective cohort study

  • by Jose M. Vela-Ruiz, Zaida Morante, Yomali Ferreyra, Marco A. Galvez-Villanueva, Fernando Valencia, J. Jhanina Campos-Tineo, Mariana Callapiña De Paz, Ariana Alessandra Córdova-Salazar, Pool Marcos-Carbajal, Joan M. Moreno Lujan, Andy R. Pantoja Lazaro, Laura G. Escobar Caipo, Gustavo A. Flores Trujillo, Teresa N. Cusma Quintana, Jhony A. De La Cruz-Vargas, Henry L. Gomez, Alonso Soto

  • June 9, 2026

Related Content

Management of toxicities from antibody – drug conjugates in breast cancer

Beyond the tumor: the role of the gut microbiome in triple-negative breast cancer

Clinician Perspectives on Implementing Breast Cancer–Related Lymphedema Prospective Screening